Capital Advisors Ltd’s Pliant Therapeutics PLRX Stock Holding History

Capital Advisors Ltd’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	31 +11	+55%	+$13	﹤0.01%	1536
2026 Q1	$0	Buy	+20	New	+$25	﹤0.01%	1546
2025 Q1	–	Sell	-13	Closed	–	–	1530
2024 Q4	$0	Hold	13	–	–	﹤0.01%	1529
2024 Q3	$0	Hold	13	–	–	﹤0.01%	1556
2024 Q2	$0	Buy	+13	New	+$168	﹤0.01%	1586

Other funds holding PLRX

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

BDFN

Bond & Devick Financial Network St. Louis Park, Minnesota $406M AUM 16.49% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Capital Advisors Ltd's PLRX Position: Q2 2026 in Review

Capital Advisors Ltd increased its Pliant Therapeutics (PLRX) stake by 55% in Q2 2026, buying an estimated $13 and bringing the position to 31 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1536.

Capital Advisors Ltd first reported a position in PLRX in Q2 2024 and has held it in 5 quarters since. 4 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Capital Advisors Ltd held 31 shares of Pliant Therapeutics worth $0 as of Q2 2026.
Capital Advisors Ltd bought 11 Pliant Therapeutics shares in Q2 2026, an estimated $13.
Pliant Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1536 holding.
Capital Advisors Ltd first reported a position in Pliant Therapeutics in Q2 2024 and has held it in 5 quarters since.
4 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.